Visit and vaccination schedules [11].

Suman Kanungo (92300)
Sachin N. Desai (554025)
Ranjan Kumar Nandy (701317)
Mihir Kumar Bhattacharya (591309)
Deok Ryun Kim (78610)
Anuradha Sinha (701318)
Tanmay Mahapatra (484660)
Jae Seung Yang (701319)
Anna Lena Lopez (92298)
Byomkesh Manna (82437)
Barnali Bannerjee (701320)
Mohammad Ali (73095)
Mandeep Singh Dhingra (701321)
Ananga Mohan Chandra (701322)
John D. Clemens (148728)
Dipika Sur (82436)
Thomas F. Wierzba (111421)

March 2015

Dose 1 of vaccine was given on day 0 in both groups, whereas dose 2 was given either on day 14 or...

Monitoring of CD4+ and CD8+ T-cell counts, viral loads and IgG reactivity profiles to HIV-1 clade C-derived proteins and peptides during infection and treatment.

Daniela Gallerano (572501)
Portia Ndlovu (572502)
Ian Makupe (572503)
Margarete Focke-Tejkl (690066)
Kerstin Fauland (690067)
Eva Wollmann (572500)
Elisabeth Puchhammer-Stöckl (475594)
Walter Keller (27042)
Elopy Sibanda (271519)
Rudolf Valenta (186284)

February 2015

Displayed are percentages of CD4+ T-cells, CD4+ and CD8+ T-cell counts, viral loads and levels of...

HIV-1 pox virus vaccination regimes used in this study.

Danushka K. Wijesundara (285880)
Charani Ranasinghe (285885)
Ronald J. Jackson (285882)
Brett A. Lidbury (623228)
Christopher R. Parish (150750)
Benjamin J. C. Quah (623229)

August 2014

24 different vaccination regimes were included based on all combinations of FPV-HIV and VV-HIV ad...

Visit and vaccination schedules [11].

Emma-Jo Hayton (595129)
Annie Rose (595130)
Umar Ibrahimsa (595131)
Mariarosaria Del Sorbo (595132)
Stefania Capone (580361)
Alison Crook (595133)
Antony P. Black (375774)
Lucy Dorrell (79653)
Tomáš Hanke (79654)

July 2014

V:P – vaccine to placebo ratio; Scr – screen; c – low dose ChAdV63.HIVconsv 5×109 vp; ...

Vaccination schedule of IAVI Phase-I prime boost HIV-1 Subtype-C prophylactic vaccine Trial-NIRT-ICMR (P001 Trial).

Sivasankaran Munusamy Ponnan (5698793)
Soumya Swaminathan (110137)
Kannan Tiruvengadam (5698796)
Vidyavijayan K. K. (5698799)
Narayana Cheedarla (5698802)
Manohar Nesakumar (5698805)
Sujitha Kathirvel (5698808)
Rajat Goyal (281619)
Nikhil Singla (5698811)
Joyeeta Mukherjee (112892)
Philip Bergin (455930)
Jakub T. Kopycinski (221464)
Jill Gilmour (10465)
Srikanth Prasad Tripathy (3846424)
Hanna Elizabeth Luke (5724728)

September 2018

Vaccination schedule of IAVI Phase-I prime boost HIV-1 Subtype-C prophylactic vaccine Trial-NIRT-ICM...

Vaccination schedule of IAVI Phase-I Prime Boost HIV-1 Subtype-C Prophylactic Vaccine Trial-NIRT-ICMR (P001 Trial).

Sivasankaran Munusamy Ponnan (5698793)
Sathyamurthy Pattabiram (6523958)
Kannan Thiruvengadam (796402)
Rajat Goyal (281619)
Nikhil Singla (5698811)
Joyeeta Mukherjee (112892)
Shweta Chatrath (6523961)
Philip Bergin (455930)
Jakub T. Kopycinski (221464)
Jill Gilmour (10465)
Sriram Kumar (4566229)
Malathy Muthu (6523964)
Sudha Subramaniam (6523967)
Soumya Swaminathan (110137)
Srikanth Prasad Tripathy (3846424)
Hanna Elizabeth Luke (5724728)

March 2019

Vaccination schedule of IAVI Phase-I Prime Boost HIV-1 Subtype-C Prophylactic Vaccine Trial-NIRT-ICM...

Number of Volunteers Enrolled, Vaccination Schedule, Sample Collection and Assessment time points.

Michael C. Keefer (102279)
Jill Gilmour (10465)
Peter Hayes (10433)
Dilbinder Gill (145107)
Jakub Kopycinski (145112)
Hannah Cheeseman (145116)
Michelle Cashin-Cox (145121)
Marloes Naarding (145126)
Lorna Clark (145131)
Natalia Fernandez (145135)
Catherine A. Bunce (145138)
Christine M. Hay (145141)
Sabrina Welsh (145145)
Wendy Komaroff (145151)
Lottie Hachaambwa (145156)
Tony Tarragona-Fiol (145159)
Eddy Sayeed (132289)
Devika Zachariah (145161)
James Ackland (145163)
Kelley Loughran (145165)
Burc Barin (145167)
Emmanuel Cormier (145169)
Josephine H. Cox (132260)
Patricia Fast (145172)
Jean-Louis Excler (132268)

August 2012

W = week, W0 and W24 are vaccination visits.a(V/P) Number of Vaccine recipients/number o...

HVTN 104 CONSORT flow diagram (A) and specimen collection schedule (B).

Kenneth H. Mayer (116219)
Kelly E. Seaton (603000)
Yunda Huang (235282)
Nicole Grunenberg (662181)
Abby Isaacs (4591450)
Mary Allen (742378)
Julie E. Ledgerwood (253787)
Ian Frank (10438)
Magdalena E. Sobieszczyk (332353)
Lindsey R. Baden (189735)
Benigno Rodriguez (89118)
Hong Van Tieu (2190166)
Georgia D. Tomaras (164058)
Aaron Deal (4591447)
Derrick Goodman (4591453)
Robert T. Bailer (241545)
Guido Ferrari (164054)
Ryan Jensen (2806675)
John Hural (173295)
Barney S. Graham (194312)
John R. Mascola (229761)
Lawrence Corey (140058)
David C. Montefiori (108747)

November 2017

T1: 20 mg/kg IV q 4 weeks with 40 mg/kg IV loading; T2: 40 mg/kg IV q 8 weeks; T3 (P3): 5 mg/kg S...

Viral dynamics during the vaccination schedule for the control Group A (n = 10) (A) and vaccine Group B (n = 10) (B).

Paolo Palma (490673)
Maria Luisa Romiti (490674)
Carla Montesano (490675)
Veronica Santilli (490676)
Nadia Mora (490677)
Angela Aquilani (490678)
Stefania Dispinseri (267159)
Hyppolite K. Tchidjou (490679)
Marco Montano (431863)
Lars E. Eriksson (490680)
Stefania Baldassari (490681)
Stefania Bernardi (475976)
Gabriella Scarlatti (165846)
Britta Wahren (2324)
Paolo Rossi (490682)

November 2013

HIV-RNA with a limit of detection of 50 copies/ml is shown as black dots, HIV-RNA ultrasensitive ...

Vaccination schedule.

Deborah F. L. King (823563)
Paul F. McKay (425686)
Jamie F. S. Mann (425685)
C. Bryn Jones (823564)
Robin J. Shattock (110684)

November 2015

Animals were vaccinated at three time points with the indicated vaccine combinations. DNA = intra...

A Phase IIB, Randomized, Double-Blind, Multicenter, Immunogenicity Study of Vacc-4x Versus Placebo in HIV-1-infected Patients

Rockstroh, J.K.
Pantaleo, G.
Pollard, R.
van Lunzen, J.
Asmuth, D.
Peters, B.
Podzamczer, D.
Lazzarin, A.
Ellefsen-Lavoie, K.
Baksaas, I.
Sommerfelt, M.A.
Wendel-Hansen, V.
Sorensen, B.

January 2011

Background: Vacc-4x is a peptide-based HIV therapeutic vaccine to conserved domains on p24Gag. Recen...

Drug specific prophylactic efficacy.

Sulav Duwal (152805)
Laura Dickinson (5394566)
Saye Khoo (575924)
Max von Kleist (152808)

February 2019

Solid and dashed colored lines depict the concentration-prophylaxis profile for the individual drugs...

Cumulative HIV-1 incidence curves for vaccine and placebo groups for Phambili and Phambili + HVTN 503-S follow-up; Phambili + HVTN 503-S curves are based on all MITT Phambili participants (n = 800) with updated HIV-1 status for the subset of participants enrolled in HVTN 503-S (n = 465).

Zoe Moodie (211088)
Barbara Metch (189683)
Linda-Gail Bekker (60754)
Gavin Churchyard (321321)
Maphoshane Nchabeleng (325727)
Koleka Mlisana (72866)
Fatima Laher (238017)
Surita Roux (325732)
Kathryn Mngadi (795219)
Craig Innes (662182)
Matsontso Mathebula (325737)
Mary Allen (742378)
Carter Bentley (795220)
Peter B. Gilbert (30581)
Michael Robertson (791255)
James Kublin (325740)
Lawrence Corey (140058)
Glenda E. Gray (230796)

September 2015

Cumulative HIV-1 incidence curves for vaccine and placebo groups for Phambili and Phambili + HVTN...

Flow chart of the RISVAC03 study design and distribution of volunteers.

Carmen Elena Gómez (123013)
Beatriz Perdiguero (123011)
Juan García-Arriaza (207920)
Victoria Cepeda (359162)
Carlos Óscar Sánchez-Sorzano (823255)
Beatriz Mothe (189474)
José Luis Jiménez (125164)
María Ángeles Muñoz-Fernández (4532437)
Jose M. Gatell (5657728)
Juan Carlos López Bernaldo de Quirós (4532431)
Christian Brander (64220)
Felipe García (111854)
Mariano Esteban (50256)

November 2015

(A) A total of 31 volunteers were randomized (21 to the MVA-B arm and 10 to the placebo arm) but ...

Vaccine immunogen HIVconsv and the design of the HIV-CORE 003 trial.

Nicola J. Borthwick (4256158)
Thirusha Lane (4278223)
Nathifa Moyo (2838644)
Alison Crook (595133)
Jung Min Shim (5233976)
Ian Baines (5233979)
Edmund G. Wee (4256161)
Philip N. Hawkins (4278214)
Julian D. Gillmore (4278211)
Tomáš Hanke (79654)
Mark B. Pepys (5233982)

May 2018

(A) Schematic representations of the HIVconsv immunogen and six pools P1-P6 of a total of 199 ove...

Dosing schedule for participants.

Suman Kanungo (92300)
Sachin N. Desai (554025)
Ranjan Kumar Nandy (701317)
Mihir Kumar Bhattacharya (591309)
Deok Ryun Kim (78610)
Anuradha Sinha (701318)
Tanmay Mahapatra (484660)
Jae Seung Yang (701319)
Anna Lena Lopez (92298)
Byomkesh Manna (82437)
Barnali Bannerjee (701320)
Mohammad Ali (73095)
Mandeep Singh Dhingra (701321)
Ananga Mohan Chandra (701322)
John D. Clemens (148728)
Dipika Sur (82436)
Thomas F. Wierzba (111421)

March 2015

Dose 1 of vaccine was given on day 0 in both groups, whereas dose 2 was given either on day 14 or...

Monitoring of CD4+ and CD8+ T-cell counts, viral loads and IgG reactivity profiles to HIV-1 clade C-derived proteins and peptides during infection and treatment.

Daniela Gallerano (572501)
Portia Ndlovu (572502)
Ian Makupe (572503)
Margarete Focke-Tejkl (690066)
Kerstin Fauland (690067)
Eva Wollmann (572500)
Elisabeth Puchhammer-Stöckl (475594)
Walter Keller (27042)
Elopy Sibanda (271519)
Rudolf Valenta (186284)

February 2015

Displayed are percentages of CD4+ T-cells, CD4+ and CD8+ T-cell counts, viral loads and levels of...

HIV-1 pox virus vaccination regimes used in this study.

Danushka K. Wijesundara (285880)
Charani Ranasinghe (285885)
Ronald J. Jackson (285882)
Brett A. Lidbury (623228)
Christopher R. Parish (150750)
Benjamin J. C. Quah (623229)

August 2014

24 different vaccination regimes were included based on all combinations of FPV-HIV and VV-HIV ad...

Visit and vaccination schedules [11].

Emma-Jo Hayton (595129)
Annie Rose (595130)
Umar Ibrahimsa (595131)
Mariarosaria Del Sorbo (595132)
Stefania Capone (580361)
Alison Crook (595133)
Antony P. Black (375774)
Lucy Dorrell (79653)
Tomáš Hanke (79654)

July 2014

V:P – vaccine to placebo ratio; Scr – screen; c – low dose ChAdV63.HIVconsv 5×109 vp; ...

Vaccination schedule of IAVI Phase-I prime boost HIV-1 Subtype-C prophylactic vaccine Trial-NIRT-ICMR (P001 Trial).

Sivasankaran Munusamy Ponnan (5698793)
Soumya Swaminathan (110137)
Kannan Tiruvengadam (5698796)
Vidyavijayan K. K. (5698799)
Narayana Cheedarla (5698802)
Manohar Nesakumar (5698805)
Sujitha Kathirvel (5698808)
Rajat Goyal (281619)
Nikhil Singla (5698811)
Joyeeta Mukherjee (112892)
Philip Bergin (455930)
Jakub T. Kopycinski (221464)
Jill Gilmour (10465)
Srikanth Prasad Tripathy (3846424)
Hanna Elizabeth Luke (5724728)

September 2018

Vaccination schedule of IAVI Phase-I prime boost HIV-1 Subtype-C prophylactic vaccine Trial-NIRT-ICM...

Vaccination schedule of IAVI Phase-I Prime Boost HIV-1 Subtype-C Prophylactic Vaccine Trial-NIRT-ICMR (P001 Trial).

Sivasankaran Munusamy Ponnan (5698793)
Sathyamurthy Pattabiram (6523958)
Kannan Thiruvengadam (796402)
Rajat Goyal (281619)
Nikhil Singla (5698811)
Joyeeta Mukherjee (112892)
Shweta Chatrath (6523961)
Philip Bergin (455930)
Jakub T. Kopycinski (221464)
Jill Gilmour (10465)
Sriram Kumar (4566229)
Malathy Muthu (6523964)
Sudha Subramaniam (6523967)
Soumya Swaminathan (110137)
Srikanth Prasad Tripathy (3846424)
Hanna Elizabeth Luke (5724728)

March 2019

Vaccination schedule of IAVI Phase-I Prime Boost HIV-1 Subtype-C Prophylactic Vaccine Trial-NIRT-ICM...

Number of Volunteers Enrolled, Vaccination Schedule, Sample Collection and Assessment time points.

Michael C. Keefer (102279)
Jill Gilmour (10465)
Peter Hayes (10433)
Dilbinder Gill (145107)
Jakub Kopycinski (145112)
Hannah Cheeseman (145116)
Michelle Cashin-Cox (145121)
Marloes Naarding (145126)
Lorna Clark (145131)
Natalia Fernandez (145135)
Catherine A. Bunce (145138)
Christine M. Hay (145141)
Sabrina Welsh (145145)
Wendy Komaroff (145151)
Lottie Hachaambwa (145156)
Tony Tarragona-Fiol (145159)
Eddy Sayeed (132289)
Devika Zachariah (145161)
James Ackland (145163)
Kelley Loughran (145165)
Burc Barin (145167)
Emmanuel Cormier (145169)
Josephine H. Cox (132260)
Patricia Fast (145172)
Jean-Louis Excler (132268)

August 2012

W = week, W0 and W24 are vaccination visits.a(V/P) Number of Vaccine recipients/number o...

HVTN 104 CONSORT flow diagram (A) and specimen collection schedule (B).

Kenneth H. Mayer (116219)
Kelly E. Seaton (603000)
Yunda Huang (235282)
Nicole Grunenberg (662181)
Abby Isaacs (4591450)
Mary Allen (742378)
Julie E. Ledgerwood (253787)
Ian Frank (10438)
Magdalena E. Sobieszczyk (332353)
Lindsey R. Baden (189735)
Benigno Rodriguez (89118)
Hong Van Tieu (2190166)
Georgia D. Tomaras (164058)
Aaron Deal (4591447)
Derrick Goodman (4591453)
Robert T. Bailer (241545)
Guido Ferrari (164054)
Ryan Jensen (2806675)
John Hural (173295)
Barney S. Graham (194312)
John R. Mascola (229761)
Lawrence Corey (140058)
David C. Montefiori (108747)

November 2017

T1: 20 mg/kg IV q 4 weeks with 40 mg/kg IV loading; T2: 40 mg/kg IV q 8 weeks; T3 (P3): 5 mg/kg S...

Viral dynamics during the vaccination schedule for the control Group A (n = 10) (A) and vaccine Group B (n = 10) (B).

Paolo Palma (490673)
Maria Luisa Romiti (490674)
Carla Montesano (490675)
Veronica Santilli (490676)
Nadia Mora (490677)
Angela Aquilani (490678)
Stefania Dispinseri (267159)
Hyppolite K. Tchidjou (490679)
Marco Montano (431863)
Lars E. Eriksson (490680)
Stefania Baldassari (490681)
Stefania Bernardi (475976)
Gabriella Scarlatti (165846)
Britta Wahren (2324)
Paolo Rossi (490682)

November 2013

HIV-RNA with a limit of detection of 50 copies/ml is shown as black dots, HIV-RNA ultrasensitive ...

Vaccination schedule.

Deborah F. L. King (823563)
Paul F. McKay (425686)
Jamie F. S. Mann (425685)
C. Bryn Jones (823564)
Robin J. Shattock (110684)

November 2015

Animals were vaccinated at three time points with the indicated vaccine combinations. DNA = intra...

A Phase IIB, Randomized, Double-Blind, Multicenter, Immunogenicity Study of Vacc-4x Versus Placebo in HIV-1-infected Patients

Rockstroh, J.K.
Pantaleo, G.
Pollard, R.
van Lunzen, J.
Asmuth, D.
Peters, B.
Podzamczer, D.
Lazzarin, A.
Ellefsen-Lavoie, K.
Baksaas, I.
Sommerfelt, M.A.
Wendel-Hansen, V.
Sorensen, B.

January 2011

Background: Vacc-4x is a peptide-based HIV therapeutic vaccine to conserved domains on p24Gag. Recen...

Drug specific prophylactic efficacy.

Sulav Duwal (152805)
Laura Dickinson (5394566)
Saye Khoo (575924)
Max von Kleist (152808)

February 2019

Solid and dashed colored lines depict the concentration-prophylaxis profile for the individual drugs...

Cumulative HIV-1 incidence curves for vaccine and placebo groups for Phambili and Phambili + HVTN 503-S follow-up; Phambili + HVTN 503-S curves are based on all MITT Phambili participants (n = 800) with updated HIV-1 status for the subset of participants enrolled in HVTN 503-S (n = 465).

Zoe Moodie (211088)
Barbara Metch (189683)
Linda-Gail Bekker (60754)
Gavin Churchyard (321321)
Maphoshane Nchabeleng (325727)
Koleka Mlisana (72866)
Fatima Laher (238017)
Surita Roux (325732)
Kathryn Mngadi (795219)
Craig Innes (662182)
Matsontso Mathebula (325737)
Mary Allen (742378)
Carter Bentley (795220)
Peter B. Gilbert (30581)
Michael Robertson (791255)
James Kublin (325740)
Lawrence Corey (140058)
Glenda E. Gray (230796)

September 2015

Cumulative HIV-1 incidence curves for vaccine and placebo groups for Phambili and Phambili + HVTN...

Flow chart of the RISVAC03 study design and distribution of volunteers.

Carmen Elena Gómez (123013)
Beatriz Perdiguero (123011)
Juan García-Arriaza (207920)
Victoria Cepeda (359162)
Carlos Óscar Sánchez-Sorzano (823255)
Beatriz Mothe (189474)
José Luis Jiménez (125164)
María Ángeles Muñoz-Fernández (4532437)
Jose M. Gatell (5657728)
Juan Carlos López Bernaldo de Quirós (4532431)
Christian Brander (64220)
Felipe García (111854)
Mariano Esteban (50256)

November 2015

(A) A total of 31 volunteers were randomized (21 to the MVA-B arm and 10 to the placebo arm) but ...

Vaccine immunogen HIVconsv and the design of the HIV-CORE 003 trial.

Nicola J. Borthwick (4256158)
Thirusha Lane (4278223)
Nathifa Moyo (2838644)
Alison Crook (595133)
Jung Min Shim (5233976)
Ian Baines (5233979)
Edmund G. Wee (4256161)
Philip N. Hawkins (4278214)
Julian D. Gillmore (4278211)
Tomáš Hanke (79654)
Mark B. Pepys (5233982)

May 2018

(A) Schematic representations of the HIVconsv immunogen and six pools P1-P6 of a total of 199 ove...

Dosing schedule for participants.

Suman Kanungo (92300)
Sachin N. Desai (554025)
Ranjan Kumar Nandy (701317)
Mihir Kumar Bhattacharya (591309)
Deok Ryun Kim (78610)
Anuradha Sinha (701318)
Tanmay Mahapatra (484660)
Jae Seung Yang (701319)
Anna Lena Lopez (92298)
Byomkesh Manna (82437)
Barnali Bannerjee (701320)
Mohammad Ali (73095)
Mandeep Singh Dhingra (701321)
Ananga Mohan Chandra (701322)
John D. Clemens (148728)
Dipika Sur (82436)
Thomas F. Wierzba (111421)

March 2015

Dose 1 of vaccine was given on day 0 in both groups, whereas dose 2 was given either on day 14 or...

Monitoring of CD4+ and CD8+ T-cell counts, viral loads and IgG reactivity profiles to HIV-1 clade C-derived proteins and peptides during infection and treatment.

Daniela Gallerano (572501)
Portia Ndlovu (572502)
Ian Makupe (572503)
Margarete Focke-Tejkl (690066)
Kerstin Fauland (690067)
Eva Wollmann (572500)
Elisabeth Puchhammer-Stöckl (475594)
Walter Keller (27042)
Elopy Sibanda (271519)
Rudolf Valenta (186284)

February 2015

Displayed are percentages of CD4+ T-cells, CD4+ and CD8+ T-cell counts, viral loads and levels of...

HIV-1 pox virus vaccination regimes used in this study.

Danushka K. Wijesundara (285880)
Charani Ranasinghe (285885)
Ronald J. Jackson (285882)
Brett A. Lidbury (623228)
Christopher R. Parish (150750)
Benjamin J. C. Quah (623229)

August 2014

24 different vaccination regimes were included based on all combinations of FPV-HIV and VV-HIV ad...

Visit and vaccination schedules [11].

Abstract

Extracted data

Visit and vaccination schedules [11].

Abstract

Extracted data

Related items

Related items